References

1.   Anderson DR, OíBrien BJ, Levine MN, et al: Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 119:1105-12, 1993

2.   Barsotti J, Gruel Y, Rosset P, et al: Comparative double-blind study of two dosage regimens of low-molecular weight heparin in elderly patients with a fracture of the neck of the femur. J Orthop Trauma 4:371-5, 1990

3.   Bergqvist D, Burmark US, Frisell J, et al: Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: A comparison with low-dose heparin. Semin Thromb Hemost 16 Suppl:19-24, 1990

4.   Bergqvist D, Burmark US, Flordal PA, et al: Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 82:496-501, 1995

5.   Bergqvist D, Benoni G, Björgell O, et al: Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 335:696-700, 1996

6.   Bergqvist D, Flordal PA, Friberg B, et al: Thromboprophylaxis with a low molecular weight heparin (Tinzaparin) in emergency abdominal surgery. A double-blind multicenter trial. Vasa 25:156-60, 1996

7.   Bounameaux H, Huber O, Khabiri E, et al: Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin. Arch Surg 128:326-8, 1993

8.   Caen JP. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery: A French multicenter trial. Thromb Haemost 59:216-20, 1988

9.   Clagett GP, Anderson FA Jr, Heit J, et al: Prevention of venous thromboembolism. Chest 108:312S-334S, 1995

10.   Colwell CW, Spiro TE. Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. Clin Orthop 319:215-22, 1995

11.   Colwell CW Jr, Spiro TE, Trowbridge AA, et al: Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of venous thrombosis after elective knee arthroplasty. Clin Orthop 321:19-27, 1995

12.   Eriksson BI, Zachrisson BE, Teger-Nilsson AC, et al: Thrombosis prophylaxis with low molecular weight heparin in total hip replacement. Br J Surg 75:1053-7, 1988

13.   Eriksson B, Risberg B. A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily prevent pulmonary embolism and venous thrombosis in patients with hip fracture [Letter]. J Trauma 30:753, 1990

14.   Eriksson BI, Kalebo P, Anthmyr BA, et al: Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement: Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg 73-A:484-93, 1991

15.   The European Fraxiparin Study (EFS) Group. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 75:1058-63, 1988

16.   Fareed J, Walenga JM, Hoppensteadt D, et al: Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemost 18 (Suppl 3):3-15, 1988

17.   Faunø P, Suomalainen O, Rehnberg V, et al: Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg 76-A:1814-8, 1994

18.   Gallus A, Cade J, Ockelford P, et al: Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. Thromb Haemost 70:562-7, 1993

19.   Geerts WH, Jay RM, Code KI, et al: A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 335:701-7, 1996

20.   Green D, Lee MY, Lim AC, et al: Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. Ann Intern Med 113:571-4, 1990

21.   Greenfield LJ, Proctor MC, Rodriguez JL, et al: Posttrauma thromboembolism prophylaxis. J Trauma 42:100-3, 1997

22.   Haas S, Blümel G. An objective evaluation of the clinical potential of low molecular weight heparins in the prevention of thromboembolism. Semin Thromb Hemost 15:424-34, 1989

23.   Hamulyak K, Lensing AW, van der Meer J, et al: Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group. Thromb Haemost 74:1428-31, 1995

24.   Heit J. Efficacy and safety of ardeparin compared to warfarin for prevention of venous thromboembolism following total knee replacement: A double-blind dose ranging [Abstract]. Thromb Haemost 73:978, 1995

25.   Hirsh J, Levine MN. Low molecular weight heparin: Laboratory properties and clinical evaluation: A review. Eur J Surg Suppl 571:9-22, 1994

26.   Hull R, Raskob G, Pineo G, et al: A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 329:1370-6, 1993

27.   Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 271:1780-5, 1994

28.   Jørgensen PS, Knudsen JB, Broeng L, et al: The thromboprophylactic effect of a low-molecular-weight heparin (Fragmin) in hip fracture surgery: A placebo-controlled study. Clin Orthop 278:95-100, 1992

29.   Kakkar VV, Cohen AT, Edmonson RA, et al: Low molecular weight versus standard heparin for prevention of thromboembolism after major abdominal surgery. Lancet 341:259-65, 1993

30.   Knudson MM, Morabito D, Paiement GD, et al: Use of low molecular weight heparin in preventing thromboembolism in trauma patients. J Trauma 41:446-59, 1996

31.   Koppenhagen K, Adolf J, Matthes M, et al: Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thromb Haemost 67:627-30, 1992

32.   Lassen MR, Borris LC, Christiansen HM, et al: Clinical trials with low molecular weight heparins in the prevention of postoperative thromboembolic complications: A meta-analysis. Semin Thromb Hemost 17 (Suppl. 3):284-90, 1991

33.   Leclerc JR, Geerts WH, Desjardins L, et al: Prevention of deep vein thrombosis after major knee surgery - a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 67:417-23, 1992

34.   Leclerc JR, Geerts, Desjardins L, et al: Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 124:619-26, 1996

35.   Leizorovicz A, Haugh MC, Chapuis FR, et al: Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 305:913-20, 1992

36.   Levine MN, Hirsh J, Gent M, et al: Prevention of deep vein thrombosis after elective hip surgery: A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 114:545-51, 1991

37.   Levine MN, Gent M, Hirsh J, et al: Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. Arch Intern Med 156:851-6, 1996

38.   McNally MA, Kernohan WG, Brown JG, et al: Prevention of venous thromboembolism after major abdominal surgery. [Letter] Lancet 341:823, 1993

39.   Menzin J, Richner R, Huse D, et al: Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: A pharmacoeconomic evaluation. Ann Pharmacother 28:271-5, 1994

40.   Menzin J, Colditz GA, Regan MM, et al: Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 155:757-64, 1995

41.   Monreal M, Lafoz E, Navarro A, et al: A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. J Trauma 29:873-5, 1989

42.   Nurmohamed MT, Rosendaal FR, Büller HR, et al: Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis. Lancet 340:152-6, 1992

43.   Nurmohamed MT, Verhaeghe R, Haas S, et al: A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg 169:567-71, 1995

44.   OíBrien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement Can Med Assoc J 150:1083-90, 1994

45.   Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thrombosis and Haemostasis 62:1046-9, 1989

46.   Oertli D, Hess P, Durig M, et al: Prevention of deep vein thrombosis in patients with hip fractures: Low molecular weight heparin versus dextran. World J Surg 16:980-5, 1992

47.   Planes A, Vochelle N, Ferru J, et al: Enoxaparine low molecular weight heparin: Its use in the prevention of deep venous thrombosis following total hip replacement. Haemostasis 16:152-8, 1986

48.   Planes A, Vochelle N, Mansat C. Prevention of deep vein thrombosis after total hip replacement by enoxaparine: Once daily injection of 40 mg versus two daily injections of 20 mg. [Abstract] Thromb Haemost 58:117, 1987

49.   Planes A, Vochelle N, Mazas F, et al: Prevention of postoperative venous thrombosis: A randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 60:407-10, 1988

50.   Planes A, Vochelle N, Fagola M, et al: Efficacy and safety of a perioperative enoxaparin regimen in total hip replacement under various anesthesias. Am J Surg 161:525-31, 1991

51.   Planes A, Vochelle N, Darmon JY, et al: Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo. Lancet 348:224-8, 1996

52.   RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg 76-A:1174-85, 1994

53.   Samama M, Bernard P, Bonnardot JP, et al: Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg 75:128-131, 1988

54.   Samama MM, Bara L, Gerotziafas GT. Mechanisms for the antithrombotic activity in man of low molecular weight heparins. Haemostasis 24:105-17, 1994

55.   Spiro TE, Johnson GJ, Christie MJ, et al: Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Ann Intern Med 121:81-9, 1994

56.   Spiro TE, Fitzgerald RH, Trowbridge AA, et al: Enoxaparin a low molecular weight heparin and warfarin for the prevention of venous thromboembolic disease after elective knee replacement surgery [Abstract]. Blood 84 (10 Suppl 1):26a, 1994

57.   Tørholm C, Broeng L, Jørgensen PS, et al: Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery: A placebo controlled study. J Bone Joint Surg 73-B:434-8, 1991

58.   Turpie AGG, Levine MN, Hirsh J, et al: A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 315:925-9, 1986

59.   Warwick D, Bannister GC, Glew D, et al: Perioperative low-molecular-weight heparin. Is it effective and safe? J Bone Joint Surg 77-B:715-9, 1995

60.   Wiig JN, Solhaug JH, Bilberg T, et al: Prophylaxis of venographically diagnosed deep vein thrombosis in gastrointestinal surgery. Multicentre trials 20 mg and 40 mg enoxaparin versus dextran. Eur J Surg 161:663-8, 1995